首页 | 本学科首页   官方微博 | 高级检索  
检索        

新药Ⅰ期临床耐受性试验中不良事件的评价方法
引用本文:裴斐,柴栋.新药Ⅰ期临床耐受性试验中不良事件的评价方法[J].中国医药导刊,2000,2(5):29-31.
作者姓名:裴斐  柴栋
作者单位:解放军总医院临床药药学研究室,北京
摘    要:目的:对新药Ⅰ期临床耐受性试验中不良事件监察的指标、评价方法、结果判定进行探讨。方法:通过对盐酸丙哌维林、两种格列美脲等三种新药单剂量口服的Ⅰ期临床耐受性试验,观察、分析其不良事件。结果:此三种新药在常规口服剂量时,有良好的耐受必性,仅有部发患出现轻度药物不良反应。结论:新药Ⅰ期临床耐受性试验中不良事件评价对发现新药不良反应苗头具有重要意义。

关 键 词:新药  Ⅰ期临床耐受试验  不良事件  评价方法  安全

Evaluation of Adverse Events in the Phase I Clinical Trial of Tolerance to New Drugs
Pei Fei,Chai Dong,Wang Rui,Fang Yi,Xue Junfeng,Wang Zhongxiao.Evaluation of Adverse Events in the Phase I Clinical Trial of Tolerance to New Drugs[J].Chinese Journal of Medicinal Guide,2000,2(5):29-31.
Authors:Pei Fei  Chai Dong  Wang Rui  Fang Yi  Xue Junfeng  Wang Zhongxiao
Abstract:Objective: To investigate the criteria, evaluation method and result judging of adverse events in the phase I clinical trial of tolerance to new drugs. Methods: Three kinds of new drugs , Propiverine hydioehloride, dimepiridc (A, B), were researched in the phase I clinical trial of tolerance (single oral dosing) to observe and analyze the adverse events . Results: The three drugs are safe in the routine oral dose. Conclusion : The phase I clinical trial of tolerance is very important for ADR surveillance of new drugs.
Keywords:phase I clinical trial  tolerance  adverse events
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号